Novotech, an Asia Pacific centered biotech CRO will be at BIO Europe (March 20-22, 2023) to meet with clinical stage biotechs and to share the benefits of Novotech’s recently expanded operations in Europe.

Novotech announced at JPMorgan that it had acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

Meanwhile, EastHORN which is retaining its brand, is now a Novotech company and is integrating into Novotech systems and processes so clients benefit from working with one CRO globally.

The acquisition is part of Novotech’s global expansion program.

EastHORN was established in 2004 and has over 250 employees.

According to the company, the acquisition of EastHORN, means biotech clients can access Novotech’s suite of early to late-phase CRO services across Europe and the U.S., with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality clinical trials.

“This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs,” said John Moller, CEO, Novotech.

“We have been working together for many years and we share a culture of clinical excellence in biotech drug development. Clients can now access our exceptional European infrastructure, local knowledge. site relationships and access to diverse patient populations.”

In Asia Pacific, Novotech has more than 50 Site Partnership agreements with major medical research institutions to deliver exclusive benefits for sponsors.